Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02771340.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationIconic Therapeutics, Inc.

• Primary IDIT-003
• Secondary IDsNCI-2017-00255
• ClinicalTrials.gov IDNCT02771340